High dose mitoxantrone with peripheral blood progenitor cell rescue: Toxicity, pharmacokinetics and implications for dosage and schedule

British Journal of Cancer

Volumn 76, Issue 6, 1997, Pages 797-804

  Ballestrero, A ^a   Ferrando, F ^a   Garuti, A ^a   Basta, P ^a   Gonella, R ^a   Esposito, M ^b   Vannozzi, M O ^b   Sorice, G ^a   Friedman, D ^a   Puglisi, M ^a   Brema, F ^c   Mela, G S ^a   Sessarego, M ^a   Patrone, F ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Dipartimento Interaziendale di Neuroscienze del Ponente Ligure   (Italy)

Author keywords

High dose chemotherapy; Mitoxantrone; Peripheral blood progenitor cells

Indexed keywords

MELPHALAN; MITOXANTRONE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; BREAST CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG USE; FEASIBILITY STUDY; FEMALE; FEVER; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM PERMISSIBLE DOSE; MUCOSA INFLAMMATION; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TOXICITY TESTING;

EID: 12644255675     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.465     Document Type: Article

References (28)

1. Alberts DS, Peng YM, Leigh S, Davis TP and Woodward DL (1985) Disposition of mitoxantrone in cancer patients. Cancer Res 45: 1879-1884
2. Attal M, Canal P, Schlaifer D, Chatelut E, Dezeuze A, Huguet F, Payen C, Pris J and Laurent G (1994) Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. J Clin Oncol 12: 141-148
3. Bowers C, Adkins D, Dunphy F, Harrison B, LeMaistre CF and Spitzer G (1993) Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer. Bone Marrow Transplant 12: 525-530
4. Canal P, Attal M, Chatelut E, Guichard S, Huguet F, Muller C, Schlaifer D, Laurent G, Houin G and Bugat R (1993) Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. Cancer Res 53: 4850-4854
5. Ehninger G, Proksch B, Heinzel G and Woodward DL (1986) Clinical pharmacology of mitoxantrone. Cancer Treat Rep 70: 1373-1378
6. Ellis ED, William SF, Moormeier JA, Kaminer LS and Bitran JD (1990) A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating dose of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies. Bone Marrow Transplant 6: 439-442
7. Feldman EJ, Alberts DS, Arlin Z, Ahmed A, Mittelman A, Baskind, Peng Y-M, Baier M and Plezia P (1993) Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 11: 2002-2009
8. Fountzilas G, Ohnuma T, Rammos K, Mindich B and Holland FJ (1986) Comparison of mitoxantrone and ametantrone in human acute myelocytic leukemia cells in culture and in bone marrow granulocyte-macrophage progenitor cells. Cancer Drug Delivery 3: 93-100
9. Freedman LS and Workman P (1988) When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans? Cancer Chemother Pharmacol 22: 95-103
10. Frei E (1995) Pharmacologic strategies for high-dose chemotherapy. In High-dose Cancer Therapy. Armitage JO and Antman KH (eds), pp. 3-16. Williams & Wilkins: Baltimore
11. Frei E and Canellos GP (1980) Dose: A critical factor in cancer therapy. Am J Med 69: 585-594
12. Gabrilove JL, Jakubosky A, Sher H, Stenberg C, Wong G, Grous J, Yagoda A, Fain K, Malcom MAS, Clarkson B, Oettgen HF, Alton K, Weite K and Souza L (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318: 1414-1422
13. Gianni AM and Bonadonna G (1989) High-dose chemo-radiotherapy for sensitive tumors: Is sequential better than concurrent drug delivery? Eur J Cancer Clin Oncol 25: 1027-1030
14. Gibaldi M and Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker: New York
15. Hollander G and Wolfe KH (1974) Nonparametric Statistical Methods. John Wiley: New York
16. Lemoli RM and Gulati SC (1993) Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony-stimulating factor and interleukin3 on hematopoietic progenitors in human long-term bone marrow cultures. Stem Cells 11: 435-444
17. Martin M (1995) High-dose chemotherapy for breast cancer: clinical advantages of autologous peripheral blood progenitor cells (PBPC) compared with autologous bone marrow transplantation (ABMT) Ann Oncol 6 (suppl. 4): S33-S37
18. Mulder POM, Sleijfer DT, Willemse PHB, De Vries EGE, Uges DRA and Mulder NH (1989) High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer Res 49: 4654-4658
19. Patrone F, Ballestrero A, Ferrando F, Brema F, Moraglio L, Valbonesi M, Basta P, Ohio R, Gobbi M, and Sessarego M (1995) Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. J Clin Oncol 13: 840-846
20. Peng YM, Ormberg D and Alberts DS (1982) Improved high-performance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantrone. J Chromatog Biomed Appl 233: 235-247
21. Richard B, Launay-Iliadis MC, Iliadis A, Just-Landi S, Blaise D, Stoppa AM, Viens P, Gaspard MH, Maraninchi D, Cano JP and Carcassonne Y (1992) Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone-marrow transplantation. Br J Cancer 65: 399-404
22. Siena S, Bregni M, Brando B, Belli N, Ravagnani F, Gandola L, Stern AC, Lansdorp PM, Bonadonna G and Gianni AM (1991) Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 77: 400-409
23. Siena S, Bregni M, Bonsi L, Strippoli P, Peccatori F, Magni M, Di Nicola M, Bagnara GP and Gianni AM (1993) Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s). Stem Cells 11 (suppl. 2): 72-75
24. Stiff PJ, McKenzie RS, Alberts DS, Sosman JA, Dolan JR, Rad N and McCloskey T (1994) Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. J Clin Oncol 12: 176-183
25. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329: 987-994
26. Van Belle SJP, dE Planque MM, Smith IE, Van Oosterom AT, Schoemaker TJ, Deneve W and McVie JG (1986) Pharmacokinetics of mitoxantrone in human following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. Cancer Chemother Pharmacol 18: 27-32
27. Von Hoff DD, Clark GM, Weiss GR, marshall MH, Buchok JB, Knight WA III and LeMaistre CF (1986) Use of in vitro dose response effect to select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 4: 1827-1834
28. Wallerstein R, Spitzer G, Dunphy F, Huan S, Hortobagyi G, Yau J, Buzdar A, Holmes F, Theriault R, Ewer M, LeMaistre CF, Dicke K and Deisseroth A (1990) A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol 8: 1782-1788